Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification to the market regarding the company's issued share capital and total voting rights as of September 30, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (25p each) | 5,662,902,704 |
| Treasury Shares | 474,194,158 |
| Total Voting Rights | 5,188,708,546 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data for previous reporting periods is included in this specific notification.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital and does not contain forward-looking statements or risk analysis.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,188,708,546) to determine disclosure thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) when calculating the denominator for ownership percentage calculations.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.